Holen Sie sich die Stockscreener-App
3.98
2.69%
-0.11
Handel nachbörslich:
3.98
Schlusskurs vom Vortag:
$4.09
Offen:
$4.1
24-Stunden-Volumen:
2.03M
Relative Volume:
2.33
Marktkapitalisierung:
$513.99M
Einnahmen:
$204.17M
Nettoeinkommen (Verlust:
$-74.00M
KGV:
-6.8918
EPS:
-0.5775
Netto-Cashflow:
$-12.84M
1W Leistung:
-1.73%
1M Leistung:
+16.89%
6M Leistung:
-17.26%
1J Leistung:
+24.76%
1-Tages-Spanne:
$3.93
$4.18
1-Wochen-Bereich:
$3.83
$4.18
52-Wochen-Spanne:
$2.90
$6.18
Cytek Biosciences Inc Stock (CTKB) Company Profile
Firmenname
Cytek Biosciences Inc
Sektor
Branche
Telefon
(877) 922-9835
Adresse
47215 LAKEVIEW BOULEVARD, FREMONT
Compare CTKB vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CTKB
Cytek Biosciences Inc
|
3.98 | 507.53M | 204.17M | -74.00M | -12.84M | -0.5775 |
ABT
Abbott Laboratories
|
88.50 | 154.45B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
301.14 | 118.05B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.14 | 103.20B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.95 | 69.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.68 | 49.68B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cytek Biosciences Inc Stock (CTKB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2025-05-09 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-01-31 | Herabstufung | Goldman | Buy → Sell |
| 2023-12-14 | Eingeleitet | Stephens | Overweight |
| 2023-07-19 | Eingeleitet | Raymond James | Mkt Perform |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
Alle ansehen
Cytek Biosciences Inc Aktie (CTKB) Neueste Nachrichten
Cytek Biosciences (CTKB) Singular Research’s Las Vegas Invitational Conference summary - Quartr
Cytek Biosciences (CTKB) director converts 43,973 RSUs to common stock - Stock Titan
[Form 4] Cytek Biosciences, Inc. Insider Trading Activity - Stock Titan
Cytek Biosciences (CTKB) director Glenn Muir files initial ownership report - Stock Titan
Cytek Biosciences (CTKB) director awarded 18,261 options plus 33,333 RSUs - Stock Titan
Cytek Biosciences (CTKB) director boosts stake with RSU exercise and new option, RSU grants - Stock Titan
Cytek Biosciences (CTKB) director exercises RSUs and receives new equity awards - Stock Titan
Cytek Biosciences (CTKB) director exercises 43,973 RSUs, granted options and RSUs - Stock Titan
Cytek Biosciences to participate at the Singular Research’s Las Vegas Invitational Conference - GlobeNewswire
Cytek Biosciences debuts Borealis spectral cytometer - SelectScience
Cytek Biosciences Shares Fall After Borealis News and Sales Exit - Bez Kabli
Cytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026 - BioSpace
Cytek Biosciences Announces Resignation of Senior Sales Executive - TipRanks
Cytek Biosciences' Philippe Busque resigns as Senior VP, Global Sales and Services - TradingView
Cytek Biosciences, Inc. Announces Resignation of Philippe Busque from Senior Vice President, Global Sales and Services, Effective June 5, 2026 - marketscreener.com
Cytek Biosciences (CTKB) SVP Global Sales and Services to step down June 5, 2026 - Stock Titan
Cytek Biosciences explores new vaccine strategies targeting mucosal immunity - Traders Union
Promising Penny Stocks To Consider In June 2026 - simplywall.st
Cytek Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026 - Moomoo
Cytek Biosciences launches on-demand webinar on hMSC variation impacting regenerative medicine - Traders Union
Cytek Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer Yan Ming - Moomoo
Cytek Biosciences schedules webinar to advance deep immunophenotyping techniques - Traders Union
Cytek Biosciences (CTKB) Edges Higher as Support Holds, Resistance in FocusRSI Overbought Alerts - The Legal Advocate
Cytek Biosciences Q1 2026 Earnings: Deep EPS Miss Fails to Dampen Investor SentimentPre-Announcement Alert - Newser
Cytek Biosciences Reaches US$487m Market Cap Benefiting Insider Stock Buying - 富途牛牛
Cytek Biosciences (CTKB) director adds 1,454 shares through RSU vesting - Stock Titan
Cytek Biosciences (CTKB) director converts 6,107 RSUs to common stock - Stock Titan
Cytek Biosciences (CTKB) CTO vests RSUs, holds 4,919,617 shares - Stock Titan
Cytek Biosciences (CTKB) SVP nets shares after RSU vesting and tax withholding - Stock Titan
Cytek Biosciences (CTKB) CEO reports RSU vesting and tax share withholding - Stock Titan
Cytek (CTKB) CFO nets shares from RSU vesting, surrenders stock for taxes - Stock Titan
Cytek Biosciences (CTKB) CLO gains shares after RSU vesting - Stock Titan
Cytek (CTKB) Q1 2026 Disappoints — EPS $-0.15 Below $-0.10 ViewsCommunity Watchlist Picks - Newser
Cytek Biosciences invites researchers to webinar unveiling novel approach to sterilizing immunity for CDI - Traders Union
CTKB: Millennium-related filers report 6.1% and 5.4% stakes (May 15, 2026) - Stock Titan
Earnings call transcript: Cytek Biosciences Q1 2026 reveals revenue growth By Investing.com - Investing.com Australia
Earnings call transcript: Cytek Biosciences Q1 2026 reveals revenue growth - Investing.com
Stephens cuts Cytek Biosciences stock price target on elevated costs By Investing.com - Investing.com Nigeria
Stephens cuts Cytek Biosciences stock price target on elevated costs - Investing.com UK
TradingKey - TradingKey
Morgan Stanley Cuts Price Target on Cytek Biosciences to $5.50 From $6, Keeps Equalweight Rating - marketscreener.com
Cytek Biosciences, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:CTKB) 2026-05-11 - Seeking Alpha
The strategic moves Cytek (CTKB) is making now (Investor Concern) 2026-05-11Dividend Growth - newser.com
Cytek Biosciences Balances Growth Momentum With Cost Pressures - The Globe and Mail
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q1 2026 Earnings Call Transcript - Insider Monkey
Cytek Biosciences, Inc. (CTKB) reports Q1 loss, beats revenue estimates - MSN
Finanzdaten der Cytek Biosciences Inc-Aktie (CTKB)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):